Virtu Financial LLC cut its stake in Allergan plc (NYSE:AGN) by 73.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,673 shares of the company’s stock after selling 21,176 shares during the quarter. Virtu Financial LLC’s holdings in Allergan were worth $1,255,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in shares of Allergan by 479.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock worth $289,000 after buying an additional 1,463 shares during the period. UBS Asset Management Americas Inc. grew its position in shares of Allergan by 13.6% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,763,209 shares of the company’s stock worth $288,426,000 after buying an additional 210,962 shares during the period. Rhumbline Advisers grew its position in shares of Allergan by 2.6% in the 4th quarter. Rhumbline Advisers now owns 534,738 shares of the company’s stock worth $87,472,000 after buying an additional 13,462 shares during the period. Levin Capital Strategies L.P. grew its position in shares of Allergan by 44.9% in the 4th quarter. Levin Capital Strategies L.P. now owns 654,173 shares of the company’s stock worth $107,010,000 after buying an additional 202,643 shares during the period. Finally, Vestpro Financial Partners Inc. dba CPF Texas purchased a new stake in shares of Allergan in the 4th quarter worth about $369,000. 79.66% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Allergan plc (NYSE:AGN) opened at $159.40 on Friday. Allergan plc has a 1 year low of $156.00 and a 1 year high of $256.80. The company has a market cap of $52,623.34, a PE ratio of -11.88, a P/E/G ratio of 1.13 and a beta of 1.19. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.88 and a current ratio of 1.16.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date is Tuesday, February 27th. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is presently -20.86%.
A number of analysts have recently weighed in on AGN shares. Royal Bank of Canada set a $250.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Sunday, October 29th. They noted that the move was a valuation call. Vetr downgraded shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 target price on the stock. in a research report on Wednesday, December 6th. Morgan Stanley set a $200.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Allergan in a research report on Wednesday, December 6th. Finally, Credit Suisse Group set a $214.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Tuesday, December 19th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $224.00.
In related news, Chairman Brent L. Saunders purchased 4,600 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were purchased at an average price of $164.74 per share, with a total value of $757,804.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 19,630 shares of company stock worth $3,211,937. Insiders own 0.36% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Virtu Financial LLC Decreases Holdings in Allergan plc (AGN)” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/virtu-financial-llc-decreases-holdings-in-allergan-plc-agn/1911480.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.